Chronic hepatitis B (HBV) infections represent a global health problem and, to date, can only be treated with chemotherapy. Now, a research team led by Rudolf Valenta from the Centre for Pathophysiology, Infectious Diseases and Immunology at MedUni Vienna has demonstrated that a protein contained in the BM32 vaccine against grass pollen allergy induces antibodies that prevent the hepatitis B virus from binding to liver cells.
HBV is usually treated with nucleoside and nucleotide analogues or with interferon. However, these forms of treatment are associated with numerous side effects. Current HBV vaccines are ineffective in ten to twenty per cent of those vaccinated.
Data from 128 people vaccinated against grass pollen allergy have shown that this BM32 vaccine contains a protein which induces highly specific antibodies and thus prevents infection. The participants developed antibodies capable of recognising and combating all known forms of the virus. The number of antibodies appears high enough to allow the vaccine to be used against the chronic form of hepatitis B, not only preventatively but also therapeutically.
References:
Medical University of Vienna
https://www.meduniwien.ac.at/web/ueber-uns/news/detailseite/2020/news-im-august-2020/chronic-hepatitis-b-vaccine-against-grass-pollen-allergy-as-a-potential-form-of-therapy/
Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32, EBioMedicine 000 (2020) 102953; https://www.thelancet.com/pdfs/journals/ebiom/PIIS2352-3964(20)30329-7.pdf